Regeneron Pharmaceuticals
REGN
1,177 hedge funds and large institutions have $75.1B invested in Regeneron Pharmaceuticals in 2023 Q3 according to their latest regulatory filings, with 111 funds opening new positions, 401 increasing their positions, 446 reducing their positions, and 87 closing their positions.
28% more first-time investments, than exits
New positions opened: 111 | Existing positions closed: 87
13% more capital invested
Capital invested by funds: $66.2B → $75.1B (+$8.91B)
4% more funds holding in top 10
Funds holding in top 10: 28 → 29 (+1)
1% more funds holding
Funds holding: 1,165 → 1,177 (+12)
0.39% less ownership
Funds ownership: 85.84% → 85.45% (-0.39%)
10% less repeat investments, than reductions
Existing positions increased: 401 | Existing positions reduced: 446
11% less call options, than puts
Call options by funds: $1.43B | Put options by funds: $1.61B
Top Buyers
| 1 |
JP Morgan Chase
New York
|
+$664M |
| 2 |
Fidelity Investments
Boston,
Massachusetts
|
+$526M |
| 3 |
WP
Woodline Partners
San Francisco,
California
|
+$69.9M |
| 4 |
D.E. Shaw & Co
New York
|
+$64.9M |
| 5 |
ZIG
Zurich Insurance Group
Zurich,
Switzerland
|
+$62.3M |
Top Sellers
| 1 |
EWA
EP Wealth Advisors
Torrance,
California
|
-$446M |
| 2 |
Capital World Investors
Los Angeles,
California
|
-$348M |
| 3 |
Massachusetts Financial Services
Boston,
Massachusetts
|
-$248M |
| 4 |
BlackRock
New York
|
-$166M |
| 5 |
Invesco
Atlanta,
Georgia
|
-$130M |
REGN Hedge Fund Activity: Q3 2023 in Review
1,177 of the 6,301 institutional investors tracked by Wall St. Rank reported a position in Regeneron Pharmaceuticals (REGN) for Q3 2023, worth a combined $75.1B — up 13% from $66.2B a quarter earlier.
Buyers outnumbered sellers: 111 funds opened new REGN positions and 87 closed out — a net gain of 24 holders — while 401 added to existing stakes and 446 trimmed.
The largest buyer was JP Morgan Chase, adding an estimated $664M. The largest seller was EP Wealth Advisors, cutting an estimated $446M.
- 1,177 institutional investors held Regeneron Pharmaceuticals (REGN) as of Q3 2023, up from 1,165 in Q2 2023.
- Funds reported $75.1B of Regeneron Pharmaceuticals stock for Q3 2023, up 13% quarter-over-quarter.
- 111 funds opened new Regeneron Pharmaceuticals positions in Q3 2023 and 87 closed out, a net change of +24 holders.
- The largest Regeneron Pharmaceuticals buyer in Q3 2023 was JP Morgan Chase, an estimated $664M added.
- The largest Regeneron Pharmaceuticals seller in Q3 2023 was EP Wealth Advisors, an estimated $446M sold.
Based on aggregated 13F filings for Q3 2023.